Dr Reddy's launches generic hypotensive injection in US
31 December 2019 | News
Dr. Reddy's Laboratories announces the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial in the U.S. Market
image credit- istock.com
Dr. Reddy’s Laboratories Ltd. has announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial, the therapeutic generic equivalent of Nitropress® (sodium nitroprusside) Injection, 50 mg/2mL vial, approved by the U.S. Food and Drug Administration (USFDA).
According to IQVIA Health, The Nitropress® brand and generics had U.S. sales of approximately $8 million MAT for the most recent twelve months ending in October 2019 .
Dr. Reddy’s Sodium Nitroprusside Injection is available in single-dose 50 mg/2 mL (25 mg/mL) vials.
Nitropress® is a trademark of Hospira, Inc.
Sodium Nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises.
